Baidu
map

Nat Biotech:美新研究可大幅增加活体肝脏体外保存时间

2019-09-12 周舟 新华网

美国研究人员提出一种可大幅延长捐献的活体肝脏保存时间的方法,未来有望为肝移植手术赢得更长的时间窗口。日前发表在英国《自然·生物技术》杂志上的研究显示,这种新的低温保存方法可以让肝脏组织的保存时间从9小时增加到27小时。

美国研究人员提出一种可大幅延长捐献的活体肝脏保存时间的方法,未来有望为肝移植手术赢得更长的时间窗口。日前发表在英国《自然·生物技术》杂志上的研究显示,这种新的低温保存方法可以让肝脏组织的保存时间从9小时增加到27小时。

传统的供体肝脏一般保存在4摄氏度条件下以保持活性,但时长如超过9小时,移植成功率就会大幅降低,因此很难供距离较远的匹配患者使用。研究人员在此前研究中通过添加改性葡萄糖化合物3-OMG和防冻液成分PEG,成功在零下6摄氏度条件下保存了具有活性的大鼠肝脏组织,但这种技术无法应用到体积为大鼠肝脏200倍的人体肝脏上。

美国哈佛大学和麻省总医院研究人员开发的这种新方法分三个步骤。研究人员首先减少了保存溶液与空气的接触,从而大幅降低了器官表面形成冰核的机会;第二步,研究人员又在保存溶液中添加了可以稳定细胞膜的海藻糖和强化3-OMG保护作用的甘油,用以保护肝脏细胞;第三步则是开发了一种新的灌注保存溶液的方法。研究人员在4摄氏度条件下用传统保存溶液进行机械灌注,向肝脏组织的毛细血管提供氧气和养分,维持器官生理状态,并在缓慢降低温度的同时,增加新添加剂浓度,给肝脏组织一定的调整时间,使保存溶液更加均匀地分布于肝脏组织中。

美国国家卫生研究院下属国家生物医学影像和生物工程研究所工程化组织项目主任塞拉·塞利莫维奇说,在器官还能保持活性的时间窗口内向匹配的接受者提供器官,是器官移植过程中最具挑战性的任务。这项成果延长了肝脏保存时间,未来有望给成千上万等待肝移植的患者带来好处。

原始出处:

Reinier J. de Vries, Shannon N. Tessier, Peony D. Banik, et.al. Supercooling extends preservation time of human livers. Nature Biotechnology 09 September 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918850, encodeId=64e8191885051, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 28 16:26:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927717, encodeId=174c192e7171d, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Fri Feb 28 21:26:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883868, encodeId=c1ff188386831, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 22:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652369, encodeId=2b98165236961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Mar 02 18:26:00 CST 2020, time=2020-03-02, status=1, ipAttribution=)]
    2020-01-28 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918850, encodeId=64e8191885051, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 28 16:26:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927717, encodeId=174c192e7171d, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Fri Feb 28 21:26:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883868, encodeId=c1ff188386831, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 22:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652369, encodeId=2b98165236961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Mar 02 18:26:00 CST 2020, time=2020-03-02, status=1, ipAttribution=)]
    2020-02-28 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918850, encodeId=64e8191885051, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 28 16:26:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927717, encodeId=174c192e7171d, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Fri Feb 28 21:26:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883868, encodeId=c1ff188386831, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 22:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652369, encodeId=2b98165236961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Mar 02 18:26:00 CST 2020, time=2020-03-02, status=1, ipAttribution=)]
    2020-03-14 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918850, encodeId=64e8191885051, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jan 28 16:26:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927717, encodeId=174c192e7171d, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Fri Feb 28 21:26:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883868, encodeId=c1ff188386831, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 14 22:26:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652369, encodeId=2b98165236961, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Mar 02 18:26:00 CST 2020, time=2020-03-02, status=1, ipAttribution=)]
    2020-03-02 shock_melon

相关资讯

肝脏上皮样血管周细胞瘤1例

患者男性,65岁。主诉因“丙肝抗体阳性15年余,间断肝区不适3年余,加重1个月”入院。患者15年前体检时发现肝功能异常,丙肝抗体阳性,查病毒复制活跃,予干扰素抗病毒治疗6个月,丙肝RNA转阴。其后每年定期复查肝功能正常、丙肝RNA<测定值。3年前患者无明显诱因出现肝区隐痛不适,呈间断发作,持续约数秒可自行缓解,余无异常。

肝脏少见肿瘤及肿瘤样病变的CT诊断

肝脏少见肿瘤及肿瘤样病变的CT诊断

Blood:血液——肝脏再生的关键!

肝脏是人体唯一可以再生的器官,然而,一些接受了肝脏切除手术的病人由于再生过程不起作用,最终不得不需要肝脏移植。

两种肝脏纤维化程度评分可用来评估住院心衰患者的死亡风险

阜外医院张健教授团队开展研究发现,Fibrosis-4指数、非酒精性脂肪肝纤维化评分(NFS)这两种肝脏纤维化程度评分,可以作为住院心衰患者的风险评估工具,且二者具有相似的应用价值。

肝脏富血供病变!

女,58岁,体检发现肝脏占位21天

盘点:肝脏良性肿瘤

随着体检的普及,越来越多人体检彩超或CT/MR发现肝囊肿、肝血管瘤,其实这些大部分都是良性的病变,本文将盘点常见和不常见的肝良性肿瘤。

Baidu
map
Baidu
map
Baidu
map